Should I Take Mounjaro? What the Clinical Evidence Actually Shows

What the SURMOUNT trial results actually measured

The question of whether to take Mounjaro is best anchored in what the evidence showed, rather than in headlines. SURMOUNT-1 (a 72-week randomised trial involving 2,539 adults with obesity, published in the New England Journal of Medicine) found that participants on the 15 mg dose lost around 20–21% of their body weight on average, alongside a reduced-calorie diet and increased activity. That is a larger average reduction than any other licensed weight-loss medicine currently available in the UK.

More recently, the SURMOUNT-5 head-to-head trial compared tirzepatide directly against semaglutide 2.4 mg (Wegovy) in adults without diabetes. Tirzepatide produced a greater average weight reduction over 72 weeks, which fed into NICE's committee discussions when they reviewed the evidence in late 2024. Results pages for individual medicines can look compelling in isolation; the head-to-head data give a cleaner read on relative effect size.

Two things the trial data cannot tell you: whether you personally will lose that much weight, and whether the medicine is safe for your specific health profile. Both depend on factors the trial averages smooth out. A prescriber uses your individual picture (weight history, comorbidities, current drugs, contraindications) to answer those questions before any prescription is issued.

Who NICE and the licensed indication say should consider it

NICE's appraisal (TA1026) recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related comorbidity. For South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, those thresholds are reduced by 2.5 kg/m² under UK guidance. NICE also specifies that if someone loses less than 5% of their body weight after six months at the highest tolerated dose, continuing treatment should be reviewed.

The licensed eligibility set by the medicine's regulators is broader: adults with a BMI of 30 or above, or 27 or above with a qualifying condition such as hypertension, high cholesterol, type 2 diabetes, obstructive sleep apnoea or prediabetes. Private prescribing follows the licensed criteria, not the narrower NICE NHS thresholds — so adults who don't meet NHS eligibility may still qualify through a private clinical assessment.

A question our prescribers hear most weeks is whether BMI alone is enough to get started, and our page on whether Mounjaro is the right choice for you works through the key considerations in full. The honest answer is that BMI is the entry criterion, but it is never the whole picture. The prescriber also considers your current medicines, your personal and family medical history, and whether any contraindications apply, including a history of pancreatitis, medullary thyroid carcinoma or MEN2 syndrome. If you take oral contraceptives, there is an absorption interaction with tirzepatide worth discussing. You can read more about who the medicine is not suitable for on our page covering conditions and situations that rule out Mounjaro.

What the decision actually involves day to day

Deciding to take Mounjaro is not just a clinical question, it is a practical one. The medicine is a once-weekly subcutaneous injection, self-administered at home. Treatment begins at 2.5 mg, which exists to let your system adjust, not to produce weight loss on its own. The prescriber then titrates the dose upward, typically in four-week steps, toward the dose where you get the best balance of effect and tolerability, and our guide on when to take Mounjaro each week covers how to build that routine consistently.

The side-effect profile matters here. GI symptoms (nausea, reflux, changes in bowel habit) are common early on, especially around dose increases. For most people they settle. For some they don't, and a prescriber needs to know, because managing them is part of supervised treatment. The NHS tirzepatide medicines page covers these in plain language, including when to get urgent medical help.

Cost is a practical factor too. Private tirzepatide is priced per four-week pen, and pen prices have risen since Eli Lilly adjusted UK list prices in September 2025, with reported market prices now roughly £149–£375 per month depending on dose and provider, a range that reflects differences in dose as well as provider, so our page on how many ml of Mounjaro you should take can help you understand where in that range you are likely to sit. If you want context on how private pricing works and what a legitimate service includes, our guide to Mounjaro costs in the UK walks through it honestly. The short version: price is not the metric that matters most for a prescription medicine, clinical safety and genuine supply chain are.

How a clinical assessment at nume works

If you are thinking seriously about whether Mounjaro is right for you, the next step is a proper consultation. At nume, that means a free assessment reviewed the same day by a GPhC-registered Independent Prescriber, a named clinician, not automated software. The process includes photo-ID and live weight verification, and a review of your medical history and current medicines before any prescribing decision is made.

If the prescriber judges you suitable, treatment is dispatched the same day for orders placed before midday on a working day, arriving by tracked DPD delivery the next working day in plain packaging. If they judge that Mounjaro is not the right fit, they will tell you why and discuss alternatives. You can find out more about how the consultation works and what going on Mounjaro involves practically before you start. When you're ready, take a look at our treatment options page to begin your free consultation.